JAMA Cardiology

SEPTEMBER 30, 2021

This cohort study examines the prevalence of epicardial coronary artery disease and coronary microvascular dysfunction in hospitalized patients with heart failure with preserved ejection fraction.

Coronary Artery Disease 40

Coronary Artery Disease Preserved Ejection Fraction Heart Failure Hospital 40

The American Journal of Cardiology

JANUARY 10, 2024

Publication date: 15 February 2024 Source: The American Journal of Cardiology, Volume 213 Author(s): Mingqiang Fu, Yanyan Wang, Xueting Han, Shuai Yuan, Yuan Liu, Juying Qian, Jingmin Zhou, Junbo Ge

Preserved Ejection Fraction 40

Preserved Ejection Fraction Coronary Artery Disease Heart Failure 40

Circulation: Heart Failure

DECEMBER 18, 2023

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Coronary microvascular dysfunction (CMD) is involved in heart failure (HF) onset and progression, independently of HF phenotype and obstructive coronary artery disease.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Coronary Artery Disease Circulation 40

DAIC

APRIL 3, 2024

Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting. Too Many Choices?

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Frontiers in Cardiovascular Medicine

AUGUST 6, 2024

In the short-term it can result in pre-eclampsia, haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, or even hypertension associated acute heart failure, all of which may necessitate pre-term delivery to prevent maternal or neonatal death.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Coronary Artery Disease Hypertension 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52